# US 2023/0021826 A1 · Differentiation method for procuring large amount of oligodendrocytes by disassembling 3d organoids generated from human pluripotent stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0021826 A1
- Document ID: US20230021826A1
- Status: Published application
- Kind: A1
- Application number: 17/787,248
- Filed: 2020-12-17
- Published: 2023-01-26
- Earliest claimed: 2019-12-17
- Assignees: Corestem Co., Ltd.
- Applicants: Corestem Co.,Ltd.
- Inventors: Sang Hun LEE; Mi Yoon CHANG; Hye Ji WOO
- Web page: https://patentgrep.com/patent/US20230021826A1

## CPC

- C12N 5/0622: {Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells}
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- C12N 2500/24: Iron; Fe chelators; Transferrin
- C12N 2500/38: Vitamins
- C12N 2500/46: Amines, e.g. putrescine
- C12N 2501/105: Insulin-like growth factors [IGF]
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/135: Platelet-derived growth factor [PDGF]
- C12N 2501/148: Transforming growth factor alpha [TGF-a]
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/385: of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
- C12N 2501/392: Sexual steroids
- C12N 2501/41: Hedgehog proteins; Cyclopamine (inhibitor)
- C12N 2503/02: Drug screening
- C12N 2506/02: from embryonic cells
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2509/10: Mechanical dissociation
- C12N 2513/00: 3D culture
- C12N 2533/32: Polylysine, polyornithine
- C12N 2533/52: Fibronectin; Laminin
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a method, which patterns 3D organoids prepared from human pluripotent stem cells and chops the same so as to culture oligodendrocyte progenitor cells, and induces the differentiation thereof so as to obtain a large quantity of finally differentiated oligodendrocytes. Compared to cells differentiated by a conventional differentiation method, oligodendrocytes obtained in a large quantity have the same or superior reproducibility, stability, and functionality and have remarkably shortened differentiation time, and thus are expected to be very useful for cell therapeutic agents or for screening for therapeutic drugs.

## Claims

### Claim 1

A method for differentiation of oligodendrocytes obtained in a large quantity, comprising:
culturing human pluripotent stem cells to prepare ventral organoids, patterning and chopping the prepared organoids to obtain a large quantity of oligodendrocyte progenitor cells; and
culturing them to differentiate into oligodendrocytes.

### Claim 2 (depends on 1)

A cell therapeutic agent comprising oligodendrocytes differentiated by the method according to claim 1.

### Claim 3 (depends on 2)

The cell therapeutic agent according to claim 2, wherein the cell therapeutic agent treats a nervous system inflammatory disease caused by oligodendrocytopathy.

### Claim 4 (depends on 3)

The cell therapeutic agent according to claim 3, wherein the nervous system inflammatory disease caused by oligodendrocytopathy is any one selected from the group consisting of multiple system atrophy (MSA), multiple sclerosis, cerebral palsy, spinal cord injury, stroke, Lewy body dementia and alpha-synucleinopathy.

### Claim 5 (depends on 1)

A drug screening method using oligodendrocytes obtained by the method according to claim 1.

### Claim 6 (depends on 5)

The drug screening method according to claim 5, wherein the drug treats a nervous system inflammatory disease caused by oligodendrocytopathy.

### Claim 7 (depends on 6)

The drug screening method according to claim 6, wherein the nervous system inflammatory disease caused by oligodendrocytopathy is one selected from the group consisting of multiple system atrophy (MSA), multiple sclerosis, cerebral palsy, spinal cord injury, stroke, Lewy body dementia and alpha-synucleinopathy.
